Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

[1]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[3]  C. Li,et al.  Analyzing high‐density oligonucleotide gene expression array data , 2001, Journal of cellular biochemistry.

[4]  C. Osborne,et al.  Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[6]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[8]  E. Mamounas.  NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. , 1997, Oncology.

[9]  E. Mamounas,et al.  Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Zhiping Hu,et al.  Herpes simplex encephalitis , 1984, The Lancet.

[11]  Richard M. Simon,et al.  A Paradigm for Class Prediction Using Gene Expression Profiles , 2003, J. Comput. Biol..